Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.43
TBUFF's Cash to Debt is ranked higher than
78% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. TBUFF: 3.43 )
TBUFF' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 3.43

Equity to Asset 0.68
TBUFF's Equity to Asset is ranked higher than
76% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. TBUFF: 0.68 )
TBUFF' s 10-Year Equity to Asset Range
Min: 0.02   Max: 0.97
Current: 0.68

0.02
0.97
F-Score: 5
Z-Score: 1.99
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -31.05
TBUFF's Operating margin (%) is ranked higher than
53% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. TBUFF: -31.05 )
TBUFF' s 10-Year Operating margin (%) Range
Min: -101.12   Max: 27.69
Current: -31.05

-101.12
27.69
Net-margin (%) -33.79
TBUFF's Net-margin (%) is ranked higher than
53% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. TBUFF: -33.79 )
TBUFF' s 10-Year Net-margin (%) Range
Min: -94.39   Max: 28.68
Current: -33.79

-94.39
28.68
ROE (%) -46.58
TBUFF's ROE (%) is ranked higher than
52% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. TBUFF: -46.58 )
TBUFF' s 10-Year ROE (%) Range
Min: -192.91   Max: 32.96
Current: -46.58

-192.91
32.96
ROA (%) -19.06
TBUFF's ROA (%) is ranked higher than
55% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. TBUFF: -19.06 )
TBUFF' s 10-Year ROA (%) Range
Min: -103.43   Max: 29.1
Current: -19.06

-103.43
29.1
ROC (Joel Greenblatt) (%) -418.34
TBUFF's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. TBUFF: -418.34 )
TBUFF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -540.86   Max: 122.99
Current: -418.34

-540.86
122.99
Revenue Growth (3Y)(%) 9.10
TBUFF's Revenue Growth (3Y)(%) is ranked higher than
77% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TBUFF: 9.10 )
TBUFF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.4   Max: 38.7
Current: 9.1

-4.4
38.7
» TBUFF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TBUFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.82
TBUFF's P/B is ranked higher than
96% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. TBUFF: 0.82 )
TBUFF' s 10-Year P/B Range
Min: 0.78   Max: 77
Current: 0.82

0.78
77
P/S 1.96
TBUFF's P/S is ranked higher than
84% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. TBUFF: 1.96 )
TBUFF' s 10-Year P/S Range
Min: 1   Max: 83
Current: 1.96

1
83
EV-to-EBIT -5.80
TBUFF's EV-to-EBIT is ranked lower than
56% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. TBUFF: -5.80 )
TBUFF' s 10-Year EV-to-EBIT Range
Min: -778.9   Max: 144.8
Current: -5.8

-778.9
144.8
Current Ratio 4.36
TBUFF's Current Ratio is ranked higher than
83% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. TBUFF: 4.36 )
TBUFF' s 10-Year Current Ratio Range
Min: 0.46   Max: 21
Current: 4.36

0.46
21
Quick Ratio 4.24
TBUFF's Quick Ratio is ranked higher than
85% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. TBUFF: 4.24 )
TBUFF' s 10-Year Quick Ratio Range
Min: 0.38   Max: 18.34
Current: 4.24

0.38
18.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.88
TBUFF's Price/Net Cash is ranked higher than
98% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TBUFF: 1.88 )
TBUFF' s 10-Year Price/Net Cash Range
Min: 1.96   Max: 33.33
Current: 1.88

1.96
33.33
Price/Net Current Asset Value 1.61
TBUFF's Price/Net Current Asset Value is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TBUFF: 1.61 )
TBUFF' s 10-Year Price/Net Current Asset Value Range
Min: 1.68   Max: 35
Current: 1.61

1.68
35
Price/Tangible Book 1.41
TBUFF's Price/Tangible Book is ranked higher than
91% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. TBUFF: 1.41 )
TBUFF' s 10-Year Price/Tangible Book Range
Min: 1.47   Max: 60.5
Current: 1.41

1.47
60.5
Price/DCF (Projected) 7.50
TBUFF's Price/DCF (Projected) is ranked higher than
77% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.02 vs. TBUFF: 7.50 )
TBUFF' s 10-Year Price/DCF (Projected) Range
Min: 1.51   Max: 37
Current: 7.5

1.51
37
Price/Median PS Value 0.53
TBUFF's Price/Median PS Value is ranked higher than
95% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. TBUFF: 0.53 )
TBUFF' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 22.09
Current: 0.53

0.3
22.09
Earnings Yield (Greenblatt) -17.20
TBUFF's Earnings Yield (Greenblatt) is ranked higher than
50% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TBUFF: -17.20 )
TBUFF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 28.6
Current: -17.2

0.7
28.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TRX.Canada,
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
» More Articles for TBUFF

Headlines

Articles On GuruFocus.com
CORRECTION FROM SOURCE: Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Confe Nov 03 2014 
Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call Nov 03 2014 
Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe Oct 30 2014 
Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C, Visken Oct 15 2014 

More From Other Websites
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K/A, Financial Statements and Exhibits Dec 09 2014
TRIBUTE PHARMACEUTICALS CANADA INC. Financials Nov 18 2014
10-Q for Tribute Pharmaceuticals Canada, Inc. Nov 12 2014
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014 Nov 10 2014
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Results of Operations and Financial... Nov 10 2014
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014 Nov 10 2014
Tribute Pharmaceuticals to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on... Nov 07 2014
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Other Events, Financial Statements and... Nov 05 2014
CORRECTION FROM SOURCE: Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results... Nov 03 2014
Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call Nov 03 2014
Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe Oct 30 2014
Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe Oct 30 2014
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 08 2014
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K/A, Entry into a Material Definitive... Oct 07 2014
Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C,... Oct 02 2014
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Regulation FD Disclosure, Financial... Sep 25 2014
Tribute Pharmaceuticals Receives 4th Uracyst(R) Patent in United States Sep 25 2014
Tribute Pharma (TBUFF) – Strong Q2 results, Revenues up by 21.4% QoQ. Expect revenue to improve in... Aug 18 2014
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Results of Operations and Financial... Aug 11 2014
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK